| |
Median TNT/OS (months)
|
|---|
| |
TNT1/OS1a
|
TNT2/OS2b
|
TNT3/OS3c
|
TNT4/OS4d
|
|---|
|
LMS
|
8.0/24.9
|
5.6/17.3
|
4.6/12.3
|
4.4/9.2
|
|
UPS
|
4.8/11.0
|
3.5/7.9
|
2.3/3.7
|
3.5/6.2
|
|
DLPS
|
4.4/11.8
|
5.1/8.8
|
2.4/6.0
|
3.2/8.5
|
|
SS
|
8.7/19.7
|
5.7/11.7
|
3.4/7.8
|
2.3/6.0
|
|
MPNST
|
4.1/12.5
|
2.8/7.0
|
3.6/8.0
|
3.7/5.4
|
-
aCalculated from the date of first-line treatment onset
-
bCalculated from the date of second-line treatment onset
-
cCalculated from the date of third-line treatment onset
-
dCalculated from the date of fourth-line treatment onset
-
DLPS dedifferentiated liposarcomas, LMS leiomyosarcomas, MPNST malignant peripheral nerve sheath sarcomas, SS synovial sarcomas, UPS undifferentiated pleomorphic sarcomas
